ClinicalTrials.gg
Drug

Imatinib clinical trials

Also written Gleevec, Glivec, STI571 and CGP 57148.

studies test it
387
open now
27
in phase 3
50
first study started
1993

How each study uses imatinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the imatinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
10 May 2001 · GLEEVEC · NDA 021335 (FDA, Drugs@FDA)
European Union
7 Nov 2001 · Glivec · EMEA/H/C/000406 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

imatinib mesylate
194
Imatinib
113
Gleevec/Glivec
6
Imatinib Mesylate (Gleevec)
4
Imatinib (Gleevec)
3

Brand

Gleevec
124

Development codes

STI571
54
CGP 57148
34
NSC-716051
13
CGP57148B
7
QTI571
2
SYO-1126
1

Other names

Glivec
69

In one entry with another drug

Given together, or one or the other

Nilotinib, Imatinib
2

Studies by the year they started

386 studies that test it; most in 2002 (42)

Studies that test imatinib, by start year
YearStudies
19931
19993
200010
200120
200242
200334
200442
200526
200632
200725
200816
200914
201010
20118
201211
20136
201412
20157
20167
20178
20187
20195
202014
20216
20224
20235
20242
20254
20265

Who runs them

Industry 70 · Other 317

Novartis Pharmaceuticals (45) · National Cancer Institute (NCI) (37) · M.D. Anderson Cancer Center (27) · Novartis (8) · Asan Medical Center (7) · Bristol-Myers Squibb (6) · University of Bologna (6) · Poitiers University Hospital (5)

Often tested with

Tested in the same studies.

Dasatinib (19) · Nilotinib (17) · Docetaxel (13) · Cytarabine (12) · Gemcitabine (9) · Capecitabine (6) · Cisplatin (6) · Everolimus (6)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 6 phase 3 studies under way

Imatinib is the comparator. A study of two new drugs counts under both.

  • 2Ponatinib · Takeda, Gruppo Italiano Malattie EMatologiche dell'Adulto · next primary completion Sep 2027
  • 1Radotinib · Il-Yang Pharm. Co., Ltd.
  • 1Asciminib · Novartis Pharmaceuticals
  • 1Blinatumomab · Gruppo Italiano Malattie EMatologiche dell'Adulto · next primary completion Sep 2027
  • 1Embibatinib · Jiangsu Hansoh Pharmaceutical Co., Ltd. · next primary completion Jul 2029
Reaching primary completion within a year · 4

Studies that test imatinib.

Studies

Open first, then newest update. How each study uses imatinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 387

See all 387 studies that test imatinib →

Given beside what is tested · 56 — imatinib is usual care or a partner of the new treatment

Showing 20 of 56.

As the comparator · 34 — what is tested is compared with imatinib

Showing 20 of 34.

Codes

What other systems call imatinib · ClinicalTrials.gg INT006552

  • MeSH (NLM) D000068877Imatinib MesylateConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) BKJ8M8G5HIIMATINIBConfirmed FDA, NLM, Wikidata
  • RxNorm 282388Confirmed FDA, Wikidata
  • Wikidata Q177094imatinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C62035ImatinibOne source FDA
  • DrugBank DB00619One source Wikidata

Also registered as imatinib mesylate (UNII 8A1O1M485B · RxNorm 284924).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.